Immuno-PET: Design options and clinical proof-of-concept

Article Oncology

89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer

I. C. Kok et al.

Summary: The study found that the uptake of Zr-89-pembrolizumab in tumor lesions correlated with treatment response and patient survival. The optimal dose was 5 mg pembrolizumab, and the optimal time point for PET scanning was day 7.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study

Joanne E. Mortimer et al.

Summary: Functional imaging with Cu-64-DOTA-trastuzumab PET/CT may predict the response to T-DM1 in breast cancer patients. This study found that patients who responded to T-DM1 had higher uptake in Cu-64-DOTA-trastuzumab PET/CT scans.

JOURNAL OF NUCLEAR MEDICINE (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer

Jasper Smit et al.

Summary: Zr-89-durvalumab is safe and may provide a better way to assess tumor PD-L1 expression in NSCLC patients treated with immunotherapy. However, further research is needed to validate its utility.

JOURNAL OF NUCLEAR MEDICINE (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody

Michael D. Farwell et al.

Summary: This study demonstrates that CD8 PET imaging with Zr-89-Df-IAB22M2C is a safe and effective method for visualizing the whole-body biodistribution of CD8+ leukocytes in tumors and reference tissues, and may predict early response to immunotherapy.

JOURNAL OF NUCLEAR MEDICINE (2022)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

ImmunoPET: harnessing antibodies for imaging immune cells

Anna M. Wu et al.

Summary: Immunotherapy for cancer has made dramatic progress but faces challenges in diagnosis, driving the need for innovative non-invasive imaging approaches. ImmunoPET, utilizing antibodies, shows promise in detecting immune cell subsets, biomarkers, and tracking cellular therapeutics in preclinical models. Advances in radionuclide availability and biopharmaceutical manufacturing infrastructure have accelerated the clinical translation of ImmunoPET, which is poised to provide key information on prognosis and monitoring immune responses to therapy in cancer and beyond.

MOLECULAR IMAGING AND BIOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma

Mohammed Al-Zubaidi et al.

Summary: Bladder cancer is a lethal disease with limited conventional imaging modalities for accurate staging. This study aims to investigate the use of (89)Zirconium-labelled girentuximab PET in the staging of bladder and urothelial carcinomas.

BMJ OPEN (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Therapeutic Response Monitoring with 89Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models

Minwoo Kang et al.

Summary: This study evaluated the feasibility of monitoring therapeutic response using Zr-89-DFO-pertuzumab immuno-PET imaging agent for HER2-targeted therapy. The results showed that Zr-89-DFO-pertuzumab can clearly visualize HER2 expressing tumors and demonstrated significant HER2 downregulation in 17-DMAG treated tumors.

PHARMACEUTICS (2022)

添加到收藏夹

Review Medicine, General & Internal

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

Reyhaneh Manafi-Farid et al.

Summary: Immuno-positron emission tomography (immunoPET) is a molecular imaging technique that combines the high sensitivity of PET with the targeted ability of monoclonal antibodies. While various radioimmunotracers have been developed, only a few have been translated into clinical practice due to issues such as slow kinetics, high physiological uptake, and heterogeneous activity. Efforts are being made to overcome these limitations and develop new tracers.

FRONTIERS IN MEDICINE (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Pretargeting: A Path Forward for Radioimmunotherapy

Sarah M. Cheal et al.

Summary: This article provides an overview of the current status of radioimmunotherapy in the treatment of human tumors, the concept and outcomes of pretargeted radioimmunotherapy in clinical trials, efforts to optimize pretargeted radioimmunotherapy, and the future outlook for this treatment approach.

JOURNAL OF NUCLEAR MEDICINE (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Impact of68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring

Nina Zhou et al.

Summary: Ga-68-HER2 affibody PET/CT imaging is a safe and effective method for noninvasively detecting HER2 status in patients with advanced gastric cancer. It provides insights into HER2 heterogeneity and organ-specific differences, aiding in individualized therapy planning.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44

Philipp Diebolder et al.

Summary: Glycoprotein CD44 and its splice variants are overexpressed in many cancers and cancer stem cells, with hyaluronic acid binding to CD44 to activate cell signaling pathways. Developing a CD44-specific antibody fragment for imaging CD44-positive cancers using PET shows potential clinical utility in cancer therapy.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study

Y. Touchefeu et al.

Summary: This pilot study evaluated the imaging performance of pretargeted immuno-PET using anti-CEA monoclonal antibody TF2 and [Ga-68]Ga-labelled IMP288 in patients with metastatic CRC. The results showed a positive reaction in 9/11 patients, with an impact on management for 2 patients.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab′)2 Fragments of Obinutuzumab in Lymphoma

Lei Kang et al.

Summary: This study successfully developed Cu-64-labeled F(ab')(2) fragments for imaging CD20 in lymphoma xenograft tumor models. The results demonstrated that Cu-64-NOTA-F(ab')(2)-obinutuzumab had rapid and sustained tumor uptake in CD20-positive lymphoma with high contrast, enabling noninvasive evaluation of CD20 levels in the clinic.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer

Inki Lee et al.

Summary: The Cu-64-NOTA-Trastuzumab PET images showed specific uptake in HER2-expressing tumors, providing a feasible and safe monitoring tool for HER2 tumor status in patients with breast cancer.

EJNMMI RESEARCH (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma

Robin I. J. Merkx et al.

Summary: This study demonstrates the safety and tolerability of Zr-89-girentuximab PET/CT imaging in patients with suspected ccRCC, providing quantitative assessment of tumor dosimetry.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake

Maryam Oroujeni et al.

Summary: The study prepared and characterized a second-generation affibody molecule ZHER2:41071 with an improved scaffold, showing promising imaging properties for HER2 expression in tumors. Compared to the first-generation affibody molecules, ZHER2:41071 demonstrated lower renal uptake and similar uptake in tumors and kidneys. The new probe [Tc-99m]Tc-ZHER2:41071 provided the best tumor-to-blood ratio for single photon emission computed tomography (SPECT) among HER2-imaging probes described in the literature so far, making it a promising candidate for further clinical translation studies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study

Caroline Bodet-Milin et al.

Summary: The study optimized pretargeting parameters for the use of anti-carcinoembryonic antigen (CEA) bispecific monoclonal antibody TF2 and the 68 Ga-labeled IMP288 peptide for immuno-PET in medullary thyroid carcinoma (MTC) patients. The immuno-PET showed a higher overall sensitivity than F-18-DOPA PET/CT for detecting metastases, except for lung metastases where CT remained the most effective examination.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Nanobodies for Medical Imaging: About Ready for Prime Time?

Lea Berland et al.

Summary: Recent advances in medical treatments, particularly for cancer patients, have significantly increased life expectancies for many patients with advanced or metastatic cancers. However, challenges remain for patients who do not respond well to treatments or experience toxic side effects. Studying cellular and molecular mechanisms underlying variable treatment responses is crucial for developing more effective therapeutics. Non-invasive imaging techniques, such as immuno-PET with nanobodies, offer promising opportunities for precise targeting and whole-body information.

BIOMOLECULES (2021)

添加到收藏夹

Article Biochemical Research Methods

Inverse electron demand Diels-Alder click chemistry for pretargeted PET imaging and radioimmunotherapy

Samantha M. Sarrett et al.

Summary: This approach utilizes the rapid, bio-orthogonal inverse electron demand Diels-Alder reaction between a radiolabeled tetrazine and a trans-cyclooctene-bearing antibody for pretargeted positron emission tomography imaging and endoradiotherapy. By labeling the antibody after it has reached its target, this method reduces radiation doses to healthy tissues while achieving high activity concentrations in target tissues. Proper training in radiation safety and the handling of laboratory mice is crucial for the successful implementation of this protocol.

NATURE PROTOCOLS (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example

Marc C. Huisman et al.

Summary: The study investigated the relationship between antibody tumor uptake and target concentration using mathematical modeling of Zr-89-labeled antibody disposition, with trastuzumab kinetics serving as an example. Results showed that Zr-89-trastuzumab uptake initially increases with increasing target concentration before leveling off, influenced by the total administered mass dose of the antibody. The findings suggest the potential of Zr-89-trastuzumab uptake in assessing target expression, while also highlighting the importance of defining clinical target positivity and considering the administered mass dose to avoid false-positive results.

EJNMMI RESEARCH (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Copper-64-Labeled Antibody Fragments for Immuno-PET/ Radioimmunotherapy with Low Renal Radioactivity Levels and Amplified Tumor -Kidney Ratios

Hiroyuki Suzuki et al.

Summary: This study assessed a molecular design to reduce renal radioactivity levels of 64Cu-labeled antibody fragments, which is useful for molecular imaging and radioimmunotherapy. The results showed a reduction in renal radioactivity levels by liberating a urinary excretory radiometabolite from the antibody fragments at the renal blush border membrane (BBM).

ACS OMEGA (2021)

添加到收藏夹

Article Chemistry, Medicinal

Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide-Cysteine Chemistry

Dora Mugoli Chigoho et al.

Summary: Immune checkpoint inhibitors targeting PD-1 and PD-L1 have shown efficacy in cancer therapy, but only 20% of patients respond positively. PD-1/PD-L1 expression assessment through tumor biopsy has limitations in considering expression heterogeneity and possible metastasis.

PHARMACEUTICALS (2021)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging

Betuel Altunay et al.

Summary: The review highlights the role of antibody fragments like nanobodies in molecular imaging and therapy for breast cancer, showing that they offer advantages such as early diagnosis, reduced radiation exposure, higher specificity, and improved tumor penetration compared to monoclonal antibodies. This suggests that nanobodies and other antibody fragments may be superior vehicles for drug delivery in breast cancer treatment.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Article Oncology

A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients

Jing Yang et al.

CANCER CELL INTERNATIONAL (2020)

添加到收藏夹

Review Chemistry, Multidisciplinary

ImmunoPET: Concept, Design, and Applications

Weijun Wei et al.

CHEMICAL REVIEWS (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Caroline Rousseau et al.

JOURNAL OF NUCLEAR MEDICINE (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging

Gary A. Ulaner et al.

RADIOLOGY (2020)

添加到收藏夹

Article Hematology

Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab

Amrita Krishnan et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Harnessing 64Cu/67Cu for a theranostic approach to pretargeted radioimmunotherapy

Outi Keinanen et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

添加到收藏夹

Article Oncology

Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy

Hannan Gao et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Radiometal-labeled anti-VCAM-1 nanobodies as molecular tracers for atherosclerosis - impact of radiochemistry on pharmacokinetics

Gezim Bala et al.

BIOLOGICAL CHEMISTRY (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

Sarah R. Verhoeff et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Copper-64 trastuzumab PET imaging: a reproducibility study

Jorge A. Carrasquillo et al.

QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer

Joseph A. O'Donoghue et al.

JOURNAL OF NUCLEAR MEDICINE (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Tumor Uptake of Cu-64-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer

Joanne E. Mortimer et al.

JOURNAL OF NUCLEAR MEDICINE (2018)

添加到收藏夹

Article Oncology

Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer

Farrokh Dehdashti et al.

BREAST CANCER RESEARCH AND TREATMENT (2018)

添加到收藏夹

Article Oncology

Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors

Stijn J. H. Waaijer et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Review Biochemical Research Methods

Recent progress using the Staudinger ligation for radiolabeling applications

Constantin Mamat et al.

JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up

Frederike Bensch et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Zr-89-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Frederike Bensch et al.

NATURE MEDICINE (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab

Christopher G. England et al.

JOURNAL OF NUCLEAR MEDICINE (2017)

添加到收藏夹

Article Medicine, Research & Experimental

Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab′)2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT

Karen Lam et al.

MABS (2017)

添加到收藏夹

Article Oncology

Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach

Aniek J. G. Even et al.

ONCOTARGET (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model

Arutselvan Natarajan et al.

MOLECULAR IMAGING AND BIOLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Yvonne W. S. Jauw et al.

PLOS ONE (2017)

添加到收藏夹

Article Oncology

PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer

Judith van Loon et al.

RADIOTHERAPY AND ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Prevention of tumor seeding during needle biopsy by chemotherapeutic-releasing gelatin sticks

Ren-Yuan Bai et al.

ONCOTARGET (2017)

添加到收藏夹

Article Multidisciplinary Sciences

A One-Pot Three-Component Double-Click Method for Synthesis of [67Cu]-Labeled Biomolecular Radiotherapeutics

Katsumasa Fujiki et al.

SCIENTIFIC REPORTS (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer

Gary A. Ulaner et al.

CLINICAL NUCLEAR MEDICINE (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Bifunctional aryliodonium salts for highly efficient radioiodination and astatination of antibodies

F. Guerard et al.

BIOORGANIC & MEDICINAL CHEMISTRY (2017)

添加到收藏夹

Article Oncology

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

G. Gebhart et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Article Biochemical Research Methods

18F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels Alder Click Chemistry

Jan-Philip Meyer et al.

BIOCONJUGATE CHEMISTRY (2016)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Phase I Study of Ga-68-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma

Marleen Keyaerts et al.

JOURNAL OF NUCLEAR MEDICINE (2016)

添加到收藏夹

Article Peripheral Vascular Disease

On the Origin of Urinary Renin A Translational Approach

Lodi C. W. Roksnoer et al.

HYPERTENSION (2016)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial

Caroline Bodet-Milin et al.

JOURNAL OF NUCLEAR MEDICINE (2016)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer

Richard Laforest et al.

MOLECULAR IMAGING AND BIOLOGY (2016)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling

Edward K. Fung et al.

EJNMMI RESEARCH (2016)

添加到收藏夹

Article Oncology

A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

Neeta Pandit-Taskar et al.

CLINICAL CANCER RESEARCH (2015)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

Kristoff Muylle et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)

添加到收藏夹

Review Biochemistry & Molecular Biology

Tumor Immunotargeting Using Innovative Radionuclides

Francoise Kraeber-Bodere et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 Epitope

Ohad Ilovich et al.

RADIOLOGY (2015)

添加到收藏夹

Article Oncology

High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer

Tao Qin et al.

ONCOTARGET (2015)

添加到收藏夹

Article Oncology

89Zr-cetuximab PET imaging in patients with advanced colorectal cancer

Catharina Willemien Menke-van der Houven van Oordt et al.

ONCOTARGET (2015)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Gallium-68-Labeled Anti-HER2 Single-Chain Fv Fragment: Development and In Vivo Monitoring of HER2 Expression

Masashi Ueda et al.

MOLECULAR IMAGING AND BIOLOGY (2015)

添加到收藏夹

Review Chemistry, Multidisciplinary

Matching chelators to radiometals for radiopharmaceuticals

Eric W. Price et al.

CHEMICAL SOCIETY REVIEWS (2014)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Using Cu-64-DOTA-Trastuzumab PET

Joanne E. Mortimer et al.

JOURNAL OF NUCLEAR MEDICINE (2014)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Quantitative ImmunoPET of Prostate Cancer Xenografts with 89Zr- and 124I-Labeled Anti-PSCA A11 Minibody

Scott M. Knowles et al.

JOURNAL OF NUCLEAR MEDICINE (2014)

添加到收藏夹

Article Urology & Nephrology

A Prospective Pilot Study of 89Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy

Joseph R. Osborne et al.

JOURNAL OF UROLOGY (2014)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer

Idris Bahce et al.

EJNMMI RESEARCH (2014)

添加到收藏夹

Meeting Abstract Oncology

PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).

Geraldine Gebhart et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

添加到收藏夹

Review Pharmacology & Pharmacy

Mapping biological behaviors by application of longer-lived positron emitting radionuclides

Yang Zhou et al.

ADVANCED DRUG DELIVERY REVIEWS (2013)

添加到收藏夹

Article Chemistry, Medicinal

Enhanced Tumor Retention of a Radiohalogen Label for Site-Specific Modification of Antibodies

C. Andrew Boswell et al.

JOURNAL OF MEDICINAL CHEMISTRY (2013)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer

Catarina Xavier et al.

JOURNAL OF NUCLEAR MEDICINE (2013)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

PET imaging with 89Zr: From radiochemistry to the clinic

Melissa A. Deri et al.

NUCLEAR MEDICINE AND BIOLOGY (2013)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET

Saiyada N. F. Rizvi et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)

添加到收藏夹

Article Chemistry, Medicinal

86Y Based PET Radiopharmaceuticals: Radiochemistry and Biological Applications

Tapan K. Nayak et al.

Medicinal Chemistry (2011)

添加到收藏夹

Article Engineering, Biomedical

A method for accurate modelling of the crystal response function at a crystal sub-level applied to PET reconstruction

S. Stute et al.

PHYSICS IN MEDICINE AND BIOLOGY (2011)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

A comparison of In-111- or Cu-64-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT

Conrad Chan et al.

EJNMMI RESEARCH (2011)

添加到收藏夹

Article Pharmacology & Pharmacy

Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer

E. C. Dijkers et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)

添加到收藏夹

Review Pharmacology & Pharmacy

Bifunctional coupling agents for radiolabeling of biornolecules and target-specific delivery of metallic radionuclides

Shuang Liu

ADVANCED DRUG DELIVERY REVIEWS (2008)

添加到收藏夹

Article Biochemical Research Methods

Feasibility of the radioastatination of a monoclonal antibody with astatine-211 purified by wet extraction

Mickael Bourgeois et al.

JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2008)

添加到收藏夹

Review Engineering, Biomedical

Recent developments in PET detector technology

Tom K. Lewellen

PHYSICS IN MEDICINE AND BIOLOGY (2008)

添加到收藏夹

Review Oncology

Paul Ehrlich's magic bullet concept: 100 years of progress

Klaus Strebhardt et al.

NATURE REVIEWS CANCER (2008)

添加到收藏夹

Article Instruments & Instrumentation

Recent advances and future advances in time-of-flight PET

William W. Moses

NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT (2007)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view

C. Andrew Boswell et al.

NUCLEAR MEDICINE AND BIOLOGY (2007)

添加到收藏夹

Article Oncology

Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (I-124-cG250) and PET in patients with renal masses: a phase I trial

Chaitanya R. Divgi et al.

LANCET ONCOLOGY (2007)

添加到收藏夹

Article Oncology

Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies

GC Jayson et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac

AT Yordanov et al.

NUCLEAR MEDICINE AND BIOLOGY (2001)

添加到收藏夹

Immuno-PET: Design options and clinical proof-of-concept

相关参考文献

导出引文

分享论文